Forte Biosciences Grants Equity Inducement Award to New Employee

Forte Biosciences Inc. has granted stock options to purchase 15,000 shares to a new non-executive employee as an inducement for employment. The options vest over four years, with 25% vesting after one year and the rest monthly over 36 months, under the 2020 Inducement Equity Incentive Plan. This announcement was made via Business Wire on November 24, 2025.

Forte Biosciences, Inc. SEC 10-Q Report

Forte Biosciences, Inc. released its Q3 2025 10-Q report, highlighting a net loss of $17.7 million, up $9.3 million from 2024, due to increased R&D expenses. The net loss per share decreased due to more shares outstanding. The company is advancing its lead product, FB102, through clinical trials for autoimmune diseases, with positive Phase 1b results in celiac disease and new trials for vitiligo and alopecia areata. Forte aims to address unmet needs in these markets and plans to maintain funding for operations over the next year.

Forte Biosciences Q3 net loss per share improves

Forte Biosciences reported an improved Q3 2025 net loss per share compared to 2024, despite increased R&D expenses due to expanded clinical trials for FB102. The company anticipates significant clinical trial readouts in 2026, viewing it as pivotal for FB102's market potential. Analysts rate the stock as a 'buy,' with a 12-month price target of $57.50, significantly above its current price. The report was generated using Reuters automation and AI.

Forte Biosciences | 8-K: FY2025 Q3 Revenue: USD 0

Forte Biosciences | 10-Q: FY2025 Q3 Revenue: USD 0